Quantification of Human Adipogenesis

This study is currently recruiting participants.
Verified September 2013 by Brigham and Women's Hospital
Information provided by (Responsible Party):
Matthew Steinhauser, MD, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
First received: December 9, 2010
Last updated: September 11, 2013
Last verified: September 2013

This pilot study is using a novel technology to measure the rate of turnover of new fat cells. There are currently two active phases of this study.

  1. The first phase involves a 3-night stay in the hospital, and 2 fat biopsies over a one month period. The fat biopsies will be looked at under a special microscope that can tell which fat cells have been recently made.
  2. The second phase involves a 1-day (no overnight) stay in the hospital, and 3 fat biopsies over a 6 month period.

Condition Intervention
Biological: 15N-Thymidine, 2H-Water

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Quantification of Human Adipogenesis

Resource links provided by NLM:

Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Quantifying human adipogenesis-counting the number of new fat cells. [ Time Frame: 4 weeks-7 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

Fat biopsy. Oral mucosal smear. White blood cells.

Estimated Enrollment: 20
Study Start Date: December 2010
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Healthy subjects
18-49 year old healthy men and women. Free of significant chronic medical illness and illicit substance abuse. Body ass index from 20 to 27. Must be able to easily 'pinch an inch' of belly fat.
Biological: 15N-Thymidine, 2H-Water

Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).

Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot).


Ages Eligible for Study:   18 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy volunteers. Aged 18-49 years. Free of significant chronic medical illness. Free of illicit substance abuse.


Inclusion Criteria:

  • Aged 18-49 years.
  • Healthy.

Exclusion Criteria:

  • Significant chronic medical illness.
  • Illicit substance or alcohol abuse.
  • Body mass index > 27 kg/meters squared.
  • Underweight (BMI < 20 kg/m2).
  • History of keloid formation (excessive scarring).
  • Pregnant.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01257997

Contact: Matthew L Steinhauser, MD 617 732 5500 ext 13202 msteinhauser@partners.org

United States, Massachusetts
Brigham and Women's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Contact: Matthew L Steinhauser, MD    617-732-5500 ext 13202    msteinhauser@partners.org   
Sponsors and Collaborators
Brigham and Women's Hospital
Principal Investigator: Matthew L Steinhauser, MD Brigham and Women's Hospital
  More Information

No publications provided

Responsible Party: Matthew Steinhauser, MD, Attending Physician, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01257997     History of Changes
Other Study ID Numbers: BWH-2010p001900
Study First Received: December 9, 2010
Last Updated: September 11, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Brigham and Women's Hospital:
No specific experimental conditions

ClinicalTrials.gov processed this record on April 15, 2014